These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12161080)

  • 1. An optimal two-stage phase II design utilizing complete and partial response information separately.
    Panageas KS; Smith A; Gönen M; Chapman PB
    Control Clin Trials; 2002 Aug; 23(4):367-79. PubMed ID: 12161080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A design of phase II cancer trials using total and complete response endpoints.
    Lu Y; Jin H; Lamborn KR
    Stat Med; 2005 Oct; 24(20):3155-70. PubMed ID: 16189806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal adaptive two-stage designs for early phase II clinical trials.
    Shan G; Wilding GE; Hutson AD; Gerstenberger S
    Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An optimal three-stage design for phase II clinical trials.
    Ensign LG; Gehan EA; Kamen DS; Thall PF
    Stat Med; 1994 Sep; 13(17):1727-36. PubMed ID: 7997706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials.
    Jin H; Wei Z
    Contemp Clin Trials; 2012 Nov; 33(6):1255-60. PubMed ID: 22772088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
    Dowlati A; Crosby L; Remick SC; Makkar V; Levitan N
    Lung Cancer; 2001 May; 32(2):155-62. PubMed ID: 11325486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
    Kunz CU; Kieser M
    Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multistage designs for phase II clinical trials: statistical issues in cancer research.
    Kramar A; Potvin D; Hill C
    Br J Cancer; 1996 Oct; 74(8):1317-20. PubMed ID: 8883425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-formulating Gehan's design as a flexible two-stage single-arm trial.
    Grayling MJ; Mander AP
    BMC Med Res Methodol; 2019 Jan; 19(1):22. PubMed ID: 30691398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Admissible two-stage designs for phase II cancer clinical trials.
    Jung SH; Lee T; Kim K; George SL
    Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.
    Zhao J; Yu M; Feng XP
    BMC Med Res Methodol; 2015 Jun; 15():48. PubMed ID: 26048655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A modification of Simon's optimal design for phase II trials when the criterion is median sample size.
    Hanfelt JJ; Slack RS; Gehan EA
    Control Clin Trials; 1999 Dec; 20(6):555-66. PubMed ID: 10588296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative designs of phase II trials considering response and toxicity.
    Jin H
    Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stochastically curtailed phase II clinical trials.
    Ayanlowo AO; Redden DT
    Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal adaptive two-stage designs for phase II cancer clinical trials.
    Englert S; Kieser M
    Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
    Shan G; Zhang H; Jiang T
    BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.
    Kim J; Schell MJ
    Oncotarget; 2019 Jul; 10(42):4255-4261. PubMed ID: 31303960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graphical search for two-stage designs for phase II clinical trials.
    Jung SH; Carey M; Kim KM
    Control Clin Trials; 2001 Aug; 22(4):367-72. PubMed ID: 11514038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.